高流量鼻导管氧疗撤机时同步降低流量与FiO2对比序贯降低的随机对照试验方案(SLOWH试验)
SLOWH试验为前瞻性随机对照试验,纳入100例符合撤机标准的成人HFNC患者,随机分为先降流量组、先降FiO2组或同步降低组,主要结局为成功撤机并维持24小时的时间,旨在评估三种撤机方法的安全性与有效性。
要点
- 同步降低流量与FiO2可能成为HFNC撤机的更优策略,尚待试验验证。
- 先降流量组:流量按10 L/min/h降至20 L/min,再按0.1/h降FiO2至0.3。
- 先降FiO2组:FiO2按0.1/h降至0.3,再按10 L/min降流量至20 L/min。
核心结论
- 该试验旨在评估同步降低流量与FiO2对比序贯降低两种方式在HFNC撤机中的安全性和有效性。
- 研究预期为HFNC撤机策略提供更好的选择依据。
研究设计与样本
- 前瞻性、研究者发起的随机对照试验,设三个实验干预组。
- 计划纳入100例接受HFNC且满足撤机标准的成人患者。
- 随机分为先降流量组(FR)、先降FiO2组(OR)或同步降低组(SR)。
关键数值与推荐
- FR组:流量先按10 L/min/h降低,达20 L/min后FiO2按0.1/h降至0.3。
- OR组:FiO2先按0.1/h降至0.3,然后流量按10 L/min降低至20 L/min。
- SR组:流量和FiO2分别按10 L/min和0.1/h同步降低。
- 撤机目标为流量20 L/min和FiO2 0.3,达到后转为常规氧疗(主要低流量鼻导管)。
- 主要结局为成功撤机并维持24小时的时间。
临床怎么用
- 该试验尚未提供临床实践推荐,需等待结果。
- 试验完成后可能基于结果推荐HFNC撤机的更优策略。
局限性
- 本文为研究方案,尚无结果数据。
- 样本量100例,可能影响统计效能。
- 单中心或有限中心的设计可能限制普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-flow nasal cannula (HFNC) oxygen therapy has been widely used in critically ill patients. Despite the effectiveness of HFNC as a treatment, optimal methods to withdraw HFNC after recovery from preexisting conditions have not been investigated to date. In this study, we will evaluate the safety and efficacy of simultaneous reduction of flow and fraction of inspired oxygen (FiO2) compared with sequential reduction of either flow first or FiO2 reduction first in patients with HFNC. METHODS/DESIGN: This is a prospective, investigator-initiated, randomized controlled trial with three experimental intervention groups. A total of 100 adult patients receiving HFNC and satisfying weaning criteria will be enrolled and randomly assigned to one of the following groups: flow reduction (FR) first, FiO2 reduction (OR) first, or simultaneous reduction (SR). In the FR group, flow will be reduced first by 10 L/min/h. When it reaches 20 L/min, FiO2 will then be reduced by 0.1 /h until it reaches 0.3. In the OR group, the FiO2 will be gradually reduced first by 0.1 /h until it reaches 0.3, then flow will be reduced by 10 L/min until it reaches 20 L/min. Finally, in the SR group, both the flow and FiO2 will be gradually reduced simultaneously by 10 L/min and 0.1/h, respectively. Weaning will proceed only when patients satisfy the weaning criteria at every weaning point. When the HFNC weaning-off targets are reached (20 L/min and 0.3 for flow and FiO2, respectively), the patient will be transferred to conventional oxygen therapy (mainly low-flow nasal prongs). The primary outcome is the time to successful weaning from HFNC for 24 h. Secondary outcomes will include the success or failure rate in weaning off HFNC and changes in arterial blood gas analyses, intolerance rate, length of hospital stay, and in-hospital mortality. DISCUSSION: This study will be the first clinical trial to investigate the safety and efficacy of three different methods of weaning in adult patients receiving HFNC. Once this study is completed, we expect to be able to suggest the better strategy for withdrawal of HFNC based on the results. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03845244. Registered on 19 February 2019.
引用
- Kim MC, Lee YJ, Park JS, et al. Simultaneous reduction of flow and fraction of inspired oxygen (FiO2) versus reduction of flow first or FiO2 first in patients ready to be weaned from high-flow nasal cannula oxygen therapy: study protocol for a randomized controlled trial (SLOWH trial). Trials. 2020. PMID: 31937322. doi:10.1186/s13063-019-4019-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。